Arbutus Biopharma Corporation

NASDAQ:ABUS

Biotechnology

Healthcare
$4.11 +1.13%

+$0.05 today

Market cap
$630.03M
Beta
0.63
P/E (TTM)
5.4
EPS (TTM)
$0.83
52W Low $3.04High $5.10

Volume 2.90M

Average 1.76M

ABUS Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Arbutus Biopharma CorporationNASDAQ: ABUS

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income turns positive

Q1 FY2026 net income was $169.7M, compared with -$24.53M a year earlier. Trailing-twelve-month net income was $160.72M. Over 3 fiscal years it compounded at -21.6% a year.

Context

  • Net income amounted to 237.9% of revenue in FY2025, down 895.2 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 1 analysts of $141.78M (+523.2%) for the fiscal year ending Dec 2026, a step up from the -52.1% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$169.7M+4618.0% QoQ
Last fiscal yearDec 2025
-$33.5M-52.1% YoY
LTMMar 2026
$160.72M+309.9% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+791.9%-258.2%-1050.1 pp
1 year-52.1%+523.2%+575.3 pp
3-year CAGR-21.6%-7.1%+14.4 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(33.5M) USD
Year-over-year change
+52.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How ABUS compares with its peers on the latest reported figures

  • ABUS's LTM Mar 2026 net income of $160.72M is the 5th largest of the 9 companies compared; the peer median is $103.71M.
  • Its year-over-year change of +309.9% is the 2nd highest of 8, against a peer median of -23.4%.
  • Net income amounts to 84.0% of revenue for ABUS, versus a peer median of 124.3%.
ABUS Competitors Peer median
Net Income for ABUS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$807.99M +353.2%—16.8%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$717.13M -2481.4%+50.8%159.1%
VIRVir Biotechnology, Inc.LTM Mar 2026$442.72M -23.4%—676.0%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$169.52M +21.5%+11.0%—
ABUSArbutus Biopharma CorporationLTM Mar 2026$160.72M +309.9%-21.6%84.0%
SLNSilence Therapeutics plcLTM Mar 2026$145.44M —+20.7%15782.6%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$61.98M -35.7%-12.4%89.6%
BNTCBenitec Biopharma Inc.LTM Mar 2026$41.54M +56.8%+27.7%—
ASMBAssembly Biosciences, Inc.LTM Mar 2026$6.38M -84.0%-59.6%9.0%
Peer median (excluding ABUS) $103.71M-23.4%+15.9%124.3%

Competitors are the stored peer set for ABUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(76.25M)(69.46M)(72.85M)(69.92M)(33.5M)
Depreciation & Amortization1.75M1.43M1.4M1.38M363K
Deferred Income Tax(8.18M)0000
Stock-Based Compensation6.42M7.18M9.3M8.99M6.95M
Change in Working Capital930K29.24M(18.23M)(2.83M)(10.02M)
Accounts Receivables413K(453K)(424K)(633K)1.38M
Inventory(1.91M)0000
Accounts Payables1.91M5.22M00(2.11M)
Other Working Capital517K24.48M(17.81M)(2.2M)(9.29M)
Other Non-Cash Items7.79M(3.75M)(5.56M)(2.47M)(3.43M)
Operating Cash Flow(67.53M)(35.36M)(85.94M)(64.85M)(39.64M)
Capital Expenditures(809K)(512K)(1.01M)(182K)0
Acquisitions (Net)1.81M0000
Purchases of Investments(82.22M)(130.43M)(80.51M)(141.51M)12.87M
Sales of Investments70.35M56M132.27M164.64M155.28M
Other Investing Activities(1.81M)020K0(152.56M)
Investing Cash Flow(12.68M)(74.94M)50.77M22.95M15.58M
Debt Repayment00000
Common Stock Issued134.67M20.32M29.85M44.12M5.72M
Common Stock Repurchased00000
Dividends Paid(12.14M)0000
Other Financing Activities14.71M11.49M795K7.87M0
Financing Cash Flow137.24M31.81M30.65M52M5.72M
Effect of Forex Changes5K(22K)25K(49K)14K
Net Change in Cash57.03M(78.51M)(4.49M)10.05M(18.32M)
Free Cash Flow(68.34M)(35.87M)(86.94M)(65.03M)(39.64M)

Arbutus Biopharma Corporation

NASDAQ:ABUS

Intrinsic Alpha fair value

Locked

Current Price

$4.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.